drugset / Trial / NCT00290927

Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

NCT00290927

Phase 3 Completed 390 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

* To evaluate the superiority in the efficacy of HMR1964 and OHA combination therapy as compared with OHA therapy. * To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy. * To evaluate the safety of HMR1964.

Timeline

Start
2003-12
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic 0.2 iu/kg Subcutaneous